302
- Weber F, Anlauf M. Treatment resistant hypertension—investigation and conservative man-
agement. Dtsch Arztebl Int. 2014;111(25):425–31. - Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, Thom
S, Williams B, Executive Committee, British Hypertension Society. Better blood pressure con-
trol: how to combine drugs. J Hum Hypertens. 2003;17(2):81–6. - Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC,
White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association
Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treat-
ment: a scientific statement from the American Heart Association professional Education
Committee of the Council for high blood pressure research. Circulation.
2008;117(25):e510–26. - Denolle T, Chamontin B, Doll G, Fauvel JP, Girerd X, Herpin D, Vaïsse B, Villeneuve F,
Halimi JM. Management of resistant hypertension. Expert consensus statement from the
French Society of Hypertension, an affiliate of the French Society of Cardiology. Presse Med.
2014;43(12 Pt 1):1325–31. - Sinnakirouchenan R, Kotchen TA. Role of sodium restriction and diuretic therapy for "resis-
tant" hypertension in chronic kidney disease. Semin Nephrol. 2014;34(5):514–9. - Manolis AJ, Kallistratos MS, Doumas M, Pagoni S, Poulimenos L. Recent advances in the
management of resistant hypertension. F1000Prime Rep. 2015;7:03. - Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R,
Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hyper-
tension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension.
2011;57(6):1069–75. - Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank
JK, Caulfield MJ, Salsbury J, MacKenzie I, Padmanabhan S, Brown MJ, British Hypertension
Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazo-
sin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a ran-
domised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. - Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relation-
ships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure,
serum potassium, and urate. Hypertension. 2012;59(6):1104–9. - Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in
reducing cardiovascular events: systematic review and network meta-analyses. Hypertension.
2012;59(6):1110–7. - Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter
BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D,
Townsend R, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz
RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in
the community a statement by the American Society of Hypertension and the International
Society of Hypertension. J Hypertens. 2014;32(1):3–15. - James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland
DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend
RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of
high blood pressure in adults: report from the panel members appointed to the eighth joint
National Committee (JNC 8). JAMA. 2014;311(5):507–20. - Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez
E, American Heart Association; American College of Cardiology; Centers for Disease Control
and Prevention. An effective approach to high blood pressure control: a science advisory from
the American Heart Association, the American College of Cardiology, and the Centers for
Disease Control and Prevention. Hypertension. 2014;63(4):878–85. - Johnson DW, Atai E, Chan M, Phoon RK, Scott C, Toussaint ND, Turner GL, Usherwood T,
Wiggins KJ, KHA-CARI. KHA-CARI guideline: early chronic kidney disease: detection, pre-
vention and management. Nephrology (Carlton). 2013;18(5):340–50.
L. Segall